SCHEMBL6508753

SCHEMBL6508753

Cc1c2c(=O)[nH]c3ccc(Cl)cc3c2nn1C1CCCCO1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.47
CSF1R P07333 3/20 0.43
IDH1 O75874 1/20 0.42
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 3/20 0.40
MAPK1 P28482 2/20 0.40
LMNA P02545 2/20 0.40
HSD17B10 Q99714 2/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
HTT P42858 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
PTGS2 P35354 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
OPRL1 P41146 1/20 0.37
HPGD P15428 2/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6510843 0.92 CHEK1 (0.47) CHEK1CSF1RIDH1ALDH1A1LMNA
SCHEMBL6046806 0.88 IDH1 (0.36) CHEK1CSF1RIDH1ALDH1A1KDM4E
SCHEMBL6512957 0.88 KDM4E (0.43) CHEK1CSF1RIDH1ALDH1A1KDM4E
SCHEMBL6522020 0.87 CHEK1 (0.43) CHEK1CSF1RIDH1ALDH1A1KDM4E
SCHEMBL6511000 0.84 PTGS2 (0.46) CSF1RALDH1A1LMNAMAPTHTT
SCHEMBL6514717 0.84 PDE2A (0.44) CHEK1CSF1RIDH1ALDH1A1KDM4E
SCHEMBL6508991 0.84 PARP1 (0.44) ALDH1A1KDM4EHSD17B10TP53MAPT
SCHEMBL6508818 0.83 CHEK1 (0.39) CHEK1CSF1RIDH1ALDH1A1KDM4E
SCHEMBL6515300 0.82 CHEK1 (0.39) CHEK1CSF1RIDH1ALDH1A1KDM4E
SCHEMBL6510097 0.82 IDH1 (0.41) CHEK1CSF1RIDH1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005108338-A1 NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS AUSPEX PHARMACEUTICALS (US) 2005-11-17 WO disclosed
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 CHEK1 3/4885CSF1R 858/4885IDH1 3267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.